Anne Maitland, MD
Allergy · Tarrytown, NYNPI 1083660047
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $213,475 of the $291,951 with a category attached, or 73.1%. Blueprint Medicines Corporation accounts for 70.0% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2023 at $95,747 and has fallen 79.3% since, to $19,787 in 2025. Among allergy clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 486 payments — averaging $600.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Blueprint Medicines Corporation$204K
- Sanofi$35K
- Regeneron Healthcare Solutions, Inc.$30K
- Genentech USA, Inc.$11K
- Novartis$8K
- CSL Behring$1K
- plus $3K from 25 others
Across 187 payments — averaging $1785.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Argenx US, Inc.$334K
What the payments were for
- Consulting fees$13,0634%
- Speaking & faculty fees$213,47573%
- Travel & lodging$53,92718%
- Food & beverage$11,3334%
- Education$1540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Blueprint Medicines Corporation | 258 | $204,311 |
| Sanofi | 49 | $34,613 |
| Regeneron Healthcare Solutions, Inc. | 45 | $29,615 |
| Genentech USA, Inc. | 21 | $11,445 |
| Novartis | 10 | $7,554 |
| CSL Behring | 16 | $1,266 |
| GSK | 20 | $478 |
| Tersera Therapeutics LLC | 5 | $458 |
| AstraZeneca | 15 | $454 |
| Alk-abello, Inc | 8 | $348 |
| Biocryst US Sales Co., LLC | 4 | $311 |
| Pharming Healthcare, Inc. | 7 | $174 |
| Dermavant Sciences, Inc. | 1 | $149 |
| Mauna Kea Technologies, Inc. | 1 | $123 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Genentech, Inc. | 2 | $79 |
| Grifols USA, LLC | 3 | $57 |
| Pfizer | 3 | $55 |
| Boehringer Ingelheim | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $40 |
| Merck | 2 | $40 |
| Regeneron | 1 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Kaleo, Inc. | 1 | $26 |
| Argenx US, Inc. | 1 | $26 |
| Optinose US, Inc. | 1 | $24 |
| Incyte Corporation | 1 | $22 |
| Shire North American Group Inc | 1 | $22 |
| Octapharma USA, Inc. | 1 | $22 |
| AbbVie | 1 | $20 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$291,951 in reported general payments places this provider in the 95th percentile of 92 allergy providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $100,519 |
| Dupixent SyringeDupilumab | 16 | $70,621 |
| XolairOmalizumab | 21 | $63,298 |
| Cromolyn Sodium | 54 | $12,183 |
| Zafirlukast | 18 | $1,632 |
| Levocetirizine Dihydrochloride | 18 | $764 |
| Famotidine | 17 | $345 |
| Montelukast Sodium | 25 | $191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $1,266 | $100,51913 claims |
| Genentech, Inc.Xolair | $79 | $63,29821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 92 allergy providers in New York.
Other allergy in Tarrytown
- Marc BraunsteinHewlett$884K
- Allison RamseyRochester$643K
- Christopher SmithHorseheads$622K
- Yudhistira PersaudBronx$127K
- Michael KatlanAlbany$91K
- Michel AklJamestown$90K
- Juan SotomayorNorth Syracuse$64K
- Alan KaufmanMount Vernon$60K
- Alissa McInerneyAstoria$38K
- Audrey WeissmanElmhurst$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.